evidence: Bavarian Nordic has received a $63m contract from the US government to produce further bulk product and final freeze-dried doses of the JYNNEOS smallpox/mpox vaccine. [...] Although the bulk of the vaccine is scheduled for manufacture in 2025, with international orders in mind to address the ongoing mpox outbreak, the delivery of the freeze-dried doses is set for 2026. [...] "While the current mpox outbreak is a reminder of how vulnerable the international community remains to infectious diseases, we are dedicated to assist all governments and organisations, not only in the current public health emergency but beyond to ensure the equitable access to our smallpox/mpox vaccine."